The official Chinese name of Erdafitinib/Boct targeted drug

Erdafitinib (Erdafitinib) is a new type of oral targeted anti-cancer drug, officially launched in China as "Erdafitinib Tablets" (trade name BALVERSA). As an innovative drug targeting fibroblast growth factor receptor (FGFR) abnormalities, the clinical value of erdafitinib lies in its ability to precisely inhibit abnormal tumor cell proliferation and angiogenesis signals, thereby delaying disease progression. FGFR is a type of receptor expressed on the cell surface. Its abnormal activation in a variety of solid tumors, including bladder cancer, cholangiocarcinoma and some hematological tumors, can promote tumor growth and metastasis. By targeting the FGFR signaling pathway, erdafitinib can exert a selective effect on abnormal tumor cells while having relatively little impact on normal cells. This is an important reason why it is regarded as a precision anti-cancer drug.

The specifications of erdafitinib tablets on the domestic market are relatively diverse, including3mg 56 tablets, 4mg 28 tablets and 5mg*28 tablets, which facilitates doctors to adjust the medication plan according to the patient's tolerance and condition. Its launch time is relatively new, so it is still in the promotion and popularization stage in the domestic pharmaceutical market. Domestic drug regulatory authorities have approved it for the treatment of advanced bladder cancer and a few other tumor types related to FGFR abnormalities, providing a new option for patients who have failed or relapsed in previous treatments. The domestic registration information, instructions and indications of the drug are consistent with those of the overseas original drug, ensuring that the efficacy and safety can be fully guaranteed.

It should be noted that as an innovative targeted drug, erdafitinib must strictly follow doctor's instructions during use, and necessary molecular testing must be performed to confirm whether the patient has FGFR gene abnormalities. This precise targeted drug strategy can not only improve efficacy, but also reduce toxic reactions to non-target cells, thereby improving the overall quality of life of patients.

Reference materials：https://www.balversa.com/